Chronic migraine

Chronic migraine is a neurologic disorder defined by frequent headache, not simply a more painful migraine attack. The International Classification of Headache Disorders (ICHD-3) requires headache on at least 15 days per month for more than three months, with migraine features on at least eight days per month. In the United States, Botox is labeled to prevent headaches in adults with chronic migraine under a related, but not identical, label definition.

Chronic Migraine Is Not Episodic Migraine

The diagnostic definition and the U.S. product label answer different questions:

Framework	Threshold or scope	What it establishes
ICHD-3 chronic migraine 🔗	Headache on at least 15 days per month for more than three months, with migraine features on at least eight days per month.	A clinical diagnostic framework that also requires relevant migraine history and exclusion of a better explanation.
U.S. Botox prescribing information 🔗	Adults with at least 15 headache days per month, with headache lasting four hours a day or longer.	The population covered by the U.S. preventive-treatment indication.
Episodic migraine	Fourteen or fewer headache days per month in the U.S. label limitation.	A separate population for which the Botox label says safety and effectiveness have not been established.

These thresholds should not be used for self-diagnosis. ICHD-3 notes that medication overuse and some other headache disorders can complicate classification, and that a headache diary is often needed to characterize a frequent pattern.

U.S. Product and Label Context

Product	U.S. status for chronic migraine	Important boundary	Source checked
Botox (onabotulinumtoxinA)	FDA-labeled for prophylaxis of headaches in adults with chronic migraine.	The therapeutic BOTOX label, not BOTOX Cosmetic, controls this use. The label does not establish pediatric efficacy or episodic-migraine prophylaxis.	Current U.S. prescribing information 🔗, checked July 22, 2026.

This product-specific relationship cannot be extended to Dysport, Xeomin, Jeuveau / Nabota, or another toxin product merely because it uses botulinum toxin type A. Approval, evidence, units, preparation, and dose patterns belong to the individual product and market.

Evidence Anchor: The PREEMPT Program

The U.S. chronic-migraine indication is grounded in the PREEMPT clinical program. A pooled analysis of two randomized, double-blind trials included 1,384 adults. At 24 weeks, mean headache days fell by 8.4 days from baseline with onabotulinumtoxinA and by 6.6 days with placebo; the between-group difference favored onabotulinumtoxinA. The trials evaluated a repeated, patterned treatment across head and neck muscles rather than a single focal injection.

The result supports prevention in the studied population; it does not show that every patient responds, that the product treats an acute migraine attack, or that outcomes transfer to another toxin product. See the pooled PREEMPT analysis 🔗 and the FDA approval package 🔗 for the trial and regulatory context.

What Treatment Success Means

Outcome	Better interpretation
Fewer headache days	Prevention aims to reduce the burden over time, not terminate an attack already underway.
Lower headache impact	Disability, daily function, and headache-related quality of life can matter alongside headache-day counts.
Response across cycles	The labeled regimen is repeat-session care; one session does not settle long-term response.
A change below 15 headache days	This may describe improvement from the chronic threshold, but ongoing diagnosis and treatment decisions remain clinical judgments.

Dose and Safety Context

The U.S. label describes a fixed, multi-site head-and-neck pattern repeated at labeled intervals. Those Botox units are specific to onabotulinumtoxinA and cannot be converted into the units of another botulinum toxin product. Unit interpretation and the dose calculation overview explain why the product name and session pattern must stay attached to any dose number.

The U.S. label carries the class boxed warning about distant spread of toxin effect. In the chronic-migraine trials, neck pain, headache, eyelid ptosis, muscular weakness, and several other adverse reactions occurred more often with Botox than placebo. The current prescribing information remains the authority for contraindications, warnings, interactions, adverse reactions, preparation, and dosing.

Chronic migraine